GRADE1-2 advanced midgut neuroendocrine tumors (NETS)

Clinical trials for GRADE1-2 advanced midgut neuroendocrine tumors (NETS) explained in plain language.

Never miss a new study

Get alerted when new GRADE1-2 advanced midgut neuroendocrine tumors (NETS) trials appear

Sign up with your email to follow new studies for GRADE1-2 advanced midgut neuroendocrine tumors (NETS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Can spacing out radioactive drug doses reduce side effects in neuroendocrine tumors?

Disease control Recruiting now

This study compares two schedules of the radioactive drug Lu177-Dotatate in 166 people with slow-growing midgut neuroendocrine tumors. One group gets the drug every 8 weeks (standard), the other every 16 weeks. The goal is to see if the less frequent schedule causes fewer blood-r…

Matched conditions: GRADE1-2 ADVANCED MIDGUT NEUROENDOCRINE TUMORS (NETS)

Phase 3 • Sponsor: Grupo Espanol de Tumores Neuroendocrinos • Aim: Disease control

Last updated Jun 26, 2026 12:58 UTC

GRADE1-2 advanced midgut neuroendocrine tumors (NETS)

Get alerted when new GRADE1-2 advanced midgut neuroendocrine tumors (NETS) trials appear

Can spacing out radioactive drug doses reduce side effects in neuroendocrine tumors?